Diets · Metabolic & Cardiometabolic
statin therapy decreases GLP-1
In plain terms: Do statins lower the appetite-and-blood-sugar hormone GLP-1?
Part of: 💊 statins
Yes — statins appear to lower this hormone via a gut-bile pathway, though the human evidence rests on one small study.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Atorvastatin lowered GLP-1 and worsened glucose tolerance via a Clostridium-bile-acid axis (reversible by UDCA) in a small trial. Real and interesting, but ONE 40-person study - Norwitz repeatedly inflates this to statins 'smashing GLP-1 into the floor.'
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Yaluri 2015 · PLoS One | in-vitro | tested-null | low | Simvastatin impaired GLP-1-pathway-restorable insulin secretion in beta-cells; GLP-1 receptor stimulation rescued statin-suppressed secretion. |
| Thomasen 2026 2026 · Endocr Connect | RCT | contradicts | moderate | atorvastatin altered enterohepatic/incretin physiology (independent group) |
| Miskelly 2026 · J Clin Endocrinol Metab | animal | mixed | moderate | Rosuvastatin acutely REDUCED postprandial GLP-1 but chronic treatment raised it (direction depends on timing) |
| Bianchettin 2026 · Am J Cardiovasc Drugs | mechanism | supports | moderate | Narrative review: statins associated with increased insulin resistance and T2D risk; situates GLP-1/incretin among glucose-metabolism effects. |
| Barale 2019 · Thromb Res | in-vitro | mixed | moderate | Hypercholesterolemia impaired GLP-1 action on platelets; simvastatin restored it (statin-by-context effect on GLP-1 signaling). |
| Higuchi 2018 · Curr Opin Lipidol | mechanism | mixed | moderate | Review: LDL-lowering statins slightly increase diabetes risk; reciprocal lipid-glucose regulation framing statin diabetogenicity. |
| Buldak 2022 · J Appl Biomed | in-vitro | supports | moderate | Atorvastatin reduced beta-cell insulin/proinsulin; GLP-1 agonist exenatide reversed it via PKA, implicating statin-GLP-1 axis disruption. |
| Sattar 2010 · Lancet | meta-analysis | supports | high | Collaborative meta-analysis of statin RCTs: statins raised incident diabetes ~9%, indicating impaired glucose handling (insulin secretion/incretin axis). |
| Carmena 2019 · Curr Atheroscler Rep | mechanism | supports | moderate | Review of statin diabetogenic mechanisms: 10-12% increased new-onset diabetes via impaired insulin secretion/sensitivity, dose-dependent. |
| Galicia-Garcia 2020 · Int J Mol Sci | observational | tested-null | low | Mechanistic review: statins impair pancreatic beta-cell insulin secretion and sensitivity; impaired GLP-1/insulinotropic signaling among pathways. |
| She J, et al. 2024 · Cell Metab | RCT | supports | moderate | RCT n=40: atorvastatin reduced GLP-1 & worsened glucose via gut bile-acid axis; UDCA rescued it |
| Kuang 2025 · bioRxiv | in-vitro | mixed | low | iPSC RNA-seq: atorvastatin/simvastatin altered lncRNA linked to new-onset diabetes susceptibility; mechanistic context for statin glycemic effect. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.